{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:58:16Z","timestamp":1790056696124,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ijrobp.2017.02.003","type":"journal-article","created":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T11:46:23Z","timestamp":1486813583000},"page":"344-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":144,"title":["Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3430-2205","authenticated-orcid":false,"given":"Andrew","family":"Bang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Wilhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke R.G.","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Cagney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayal A.","family":"Aizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spektor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy A.","family":"Balboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2017.02.003_bib1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib3","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib4","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.ijrobp.2017.02.003_bib8","doi-asserted-by":"crossref","first-page":"TPS6084","DOI":"10.1200\/jco.2015.33.15_suppl.tps6084","article-title":"KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer","volume":"33","author":"Cohen","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib11","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib12","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the antiPD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib13","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-deathreceptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib17","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib18","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.18632\/oncotarget.2980","article-title":"PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma","volume":"6","author":"Luke","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib19","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1200\/JCO.2014.55.1143","article-title":"Role of radiation therapy in palliative care of the patient with cancer","volume":"32","author":"Lutz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib20","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1200\/JCO.2014.55.9567","article-title":"Radical irradiation of extracranial metastases","volume":"32","author":"Salama","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib21","first-page":"219","article-title":"Immune effects of targeted radiation therapy for cancer","volume":"19","author":"Sridharan","year":"2015","journal-title":"Discov Med"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijrobp.2016.04.017","article-title":"Safety and efficacy of radiation therapy in advanced melanoma treated with ipilimumab","volume":"96","author":"Qin","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2016.05.014","article-title":"Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer","volume":"98","author":"Boyer","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib24","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1038\/onc.2015.5","article-title":"Review of immune-related adverse events in prostate cancer patients with ipilimumab: MD Anderson experience","volume":"34","author":"Gao","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib26","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.ijrobp.2016.02.067","article-title":"The promise of the abscopal effect and the future of trials combining immunotherapy and radiation therapy","volume":"95","author":"Johnson","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib27","unstructured":"Bristol-Myers Squibb. Algorithm for suspected immune-related adverse events. Available at: www.nwcscnsenate.nhs.uk\/files\/5314\/7394\/1043\/IPI_IRAEs_ALGORITHM.pdf. Accessed December 1,\u00a02016."},{"key":"10.1016\/j.ijrobp.2017.02.003_bib28","unstructured":"Merck Oncology. A guide to monitoring patients during the treatment with Keytruda. Available at: https:\/\/www.keytruda.com\/static\/pdf\/guide-for-keytruda.pdf. Accessed December 1,\u00a02016."},{"key":"10.1016\/j.ijrobp.2017.02.003_bib29","unstructured":"Bristol-Myers Squibb. Immune-mediated adverse reactions management guide. Available at: www.opdivoyervoyhcp.com\/servlet\/servlet.FileDownload?file=00Pi000000SRPWfEAP. Accessed December 1,\u00a02016."},{"key":"10.1016\/j.ijrobp.2017.02.003_bib30","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed May 5,\u00a02016."},{"key":"10.1016\/j.ijrobp.2017.02.003_bib31","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib32","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cam4.140","article-title":"Ipilimumab and radiation therapy for melanoma brain metastases","volume":"2","author":"Silk","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","article-title":"Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival","volume":"117","author":"Knisely","year":"2012","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/CMR.0b013e32835f3d90","article-title":"Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery","volume":"23","author":"Mathew","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1158\/2326-6066.CIR-13-0082","article-title":"Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma","volume":"1","author":"Barker","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib36","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ijrobp.2016.07.005","article-title":"A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma","volume":"96","author":"Hiniker","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib37","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijrobp.2012.03.017","article-title":"The abscopal effect associated with a systemic anti-melanoma immune response","volume":"85","author":"Stamell","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib40","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib41","doi-asserted-by":"publisher","first-page":"e28780","DOI":"10.4161\/onci.28780","article-title":"Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy","volume":"3","author":"Grimaldi","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib42","doi-asserted-by":"publisher","first-page":"e1046028","DOI":"10.1080\/2162402X.2015.1046028","article-title":"A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab","volume":"4","author":"Chandra","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2017.02.003_bib43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint","year":"2015","journal-title":"Nature"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030161730319X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030161730319X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T01:11:24Z","timestamp":1658625084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030161730319X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S036030161730319X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.02.003","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}